Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1Phase 4 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 277Pain, Postoperative 14Neoplasm Metastasis 12Neoplasms 9Prostatic Neoplasms 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Pain 6Osteoporosis 6Seroma 5Colorectal Neoplasms 5Cardiotoxicity 5Breast Diseases 4Breast Cancer Female 4Neutropenia 3Melanoma 3Mastodynia 3Lymphedema 3Lung Neoplasms 3Head and Neck Neoplasms 3Brain Neoplasms 3Bone Diseases, Metabolic 3Vomiting 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sleep Initiation and Maintenance Disorders 2Skin Diseases 2Obesity 2Neurotoxicity Syndromes 2Multiple Myeloma 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × HER2 Positive Breast Cancer × Breast × Clear all
NCT06868017 2025-03-10

Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

The First Hospital of Jilin University

Phase 4 Not yet recruiting
208 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡